Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)
| 67.50 Delayed Data As of Jan 22 |  +3.73 / +5.85%Today’s Change | 8.51 Today|||52-Week Range 129.71 | +55.60% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.8B |
Company Description
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Contact Information
Arcturus Therapeutics Holdings, Inc. 10628 Science Center Drive San Diego California 92121 |
Employees
Shareholders
| Mutual fund holders | 47.92% |
| Other institutional | 30.31% |
| Individual stakeholders | 18.39% |
Top Executives
| Joseph E. Payne | President, Chief Executive Officer & Director |
| Padmanabh Chivukula | Secretary, Chief Operating & Scientific Officer |
| Andrew H. Sassine | Chief Financial Officer & Director |
| Steven G. Hughes | Chief Development Officer |
| Keith Kummerfeld | Vice President-Finance & Controller |
